Lupus Therapeutics Global Market Report 2024

Lupus therapeutics encompass treatments and medications specifically designed to manage and alleviate the symptoms of lupus, an autoimmune disease in which the body's immune system attacks its own tissues, causing inflammation and damage in various organs. These treatments aim to reduce inflammation, suppress the overactive immune response, and improve patients' quality of life.

The primary types of lupus therapeutics include systemic lupus erythematosus, cutaneous lupus erythematosus, drug-induced lupus erythematosus, neonatal lupus, and others. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects various organs and tissues, characterized by inflammation and damage to these organs. Treatments for lupus include non-steroidal anti-inflammatory drugs (NSAIDs), biologics, antimalarial drugs, corticosteroids, and others. These drugs can be administered orally, subcutaneously, intravenously, and by other methods, and are used in various settings, such as hospitals and clinics, diagnostic laboratories, and others.

The lupus therapeutics research report is one of a series of new reports that provides lupus therapeutics market statistics, including the lupus therapeutics industry's global market size, regional shares, competitors with a lupus therapeutics market share, detailed lupus therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the lupus therapeutics industry. This lupus therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lupus therapeutics market size has grown strongly in recent years. It will grow from $2.53 billion in 2023 to $2.74 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The growth during the historic period can be attributed to the increased prevalence of lupus, higher investment in healthcare infrastructure, high disposable income, strong demand for effective therapies, and the rising geriatric population.

The lupus therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.83 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The anticipated growth can be attributed to increasing drug approvals and launches, emerging markets, improvements in disease awareness and diagnosis, rising awareness initiatives, and immunosuppressive products. Major trends during the forecast period include chimeric antigen receptor T-cell (CAR-T) therapy, small molecule therapeutics for lupus, CAR-NK therapy for lupus, combined inhibition of human plasmacytoid dendritic cell activity during systemic lupus erythematosus (SLE), and urine proteomics.

The growth of the lupus therapeutics market is expected to be propelled by increasing research and development activities. These activities encompass systematic investigation and experimentation aimed at advancing knowledge, technology, or product development across various fields. They are driven by the need for innovation, technological advancements, addressing emerging challenges, improving healthcare outcomes, and fostering economic growth through scientific and technological breakthroughs. Research and development efforts contribute to advancing lupus therapeutics by discovering new treatments, enhancing existing therapies, and deepening understanding of the disease's underlying mechanisms. For instance, a March 2023 report from the Congressional Research Service highlighted that the national institutes of health received $49.183 billion in 2023 for research and development activities, marking an increase from $42.941 billion allocated in 2021. This funding underscores the growing commitment to advancing medical research, including efforts related to lupus therapeutics, thereby driving market growth.

In the lupus therapeutics market, major companies are focused on developing advanced blood tests incorporating predictive artificial intelligence to improve diagnostic accuracy and treatment efficacy. These blood tests utilize AI algorithms to analyze biomarkers in blood samples, predicting disease outcomes or treatment responses more accurately. For example, AMPEL BioSolutions LLC, a US-based precision medicine company, launched the LuGENE blood test in March 2024. This innovative test predicts lupus flares and identifies drug targets through gene expression analysis with predictive AI. It aims to revolutionize lupus management by offering personalized treatment options based on real-time abnormalities in gene expression linked to inflammation and immune dysfunction.

In April 2024, Takeda Pharmaceutical Company Limited, a Japan-based biotechnology firm, acquired Nimbus Therapeutics' TYK2 program from Nimbus Lakshmi Inc. This strategic acquisition enhances Takeda's position in the immunology market and expands its portfolio of treatments for immune-mediated diseases, including lupus. Nimbus Lakshmi Inc., based in the US, specializes in developing drugs for various conditions, including lupus and psoriasis.

Major companies operating in the lupus therapeutics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Roche Holdings Inc., GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Ltd, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited.

North America was the largest region in the lupus therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lupus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lupus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lupus therapeutics market consists of revenues earned by entities by providing services such as autoantibody testing, anti-phospholipid antibody testing, and rheumatoid factor testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The lupus therapeutics market also includes sales of calcineurin inhibitors, immunosuppressants, anticoagulants, and antimalarial drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.